Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Chordoma × Pemetrexed × Clear all

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 81 Lung Neoplasms 34 Meningeal Carcinomatosis 11 Neoplasms 8 Neoplasm Metastasis 8 Colorectal Neoplasms 6 Adenocarcinoma of Lung 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Mesothelioma, Malignant 4 Carcinoma 4 Advanced Solid Tumors 3 Pancreatic Neoplasms 2 Non-squamous Non-small Cell Lung Cancer 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 NSCLC 2 Mesothelioma 2 Melanoma 2 Endometrial Neoplasms 2 Carcinoma, Bronchogenic 2 Bronchial Neoplasms 2 Breast Neoplasms 2 Vaccinia 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thoracic Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sexual Dysfunction, Physiological 1 Respiratory Tract Neoplasms 1

Interventions

tazemetostat 1 pembrolizumab 1 Zoledronic Acid 1 Pemetrexed 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute

Phase 2 Recruiting

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡